Retatrutide’s Phase 3 results are here. It still isn’t FDA-approved.

What was announced

On July 23, Lilly reported positive topline results from TRIUMPH-2 and TRIUMPH-3, two 80-week randomized Phase 3 studies of once-weekly retatrutide. The company reported average weight loss of up to 20.8% in TRIUMPH-2 and 22.6% in TRIUMPH-3.[1]

Maximum reported treatment-arm averages, not a promise of individual response. The full data tables, estimands, discontinuation analyses and subgroup results were not available in a peer-reviewed report when this note was published.

What the headline numbers do—and do not—tell us

A press release is useful evidence of what a sponsor says its trial found. It is not interchangeable with a journal article, regulatory review or underlying dataset. ClinicalTrials.gov establishes the protocols and registered outcomes; it does not supply the absent full result tables by itself.[2][3]

Why it is called a “triple agonist”

Retatrutide is a single engineered peptide that activates three related receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. Structural work shows that the same molecule engages each receptor, with engineered signaling properties rather than three drugs mixed together.[5]

The earlier peer-reviewed Phase 2 trial randomized 338 adults. At 48 weeks, the reported mean change was −24.2% in the 12 mg group versus −2.1% with placebo; gastrointestinal adverse events were the most common and were partly mitigated with a lower starting dose.[4] Phase 3 matters because it tests the program in larger, more specific populations over a longer period—it does not erase the need to inspect the full safety and efficacy record.

A BLA is an application, not an approval date

Lilly says it plans to submit a Biologics License Application in the first quarter of 2027.[1] FDA describes a BLA as a request for permission to introduce a biological product into interstate commerce. A BLA is a request for approval—not approval itself.[6]

The filing route has an unusual backstory. FDA’s statutory definition generally treats a specifically defined amino-acid polymer greater than 40 amino acids as a “protein”; retatrutide is commonly described as a 39-amino-acid peptide. Lilly and FDA have disputed its classification, an issue now reflected in litigation and legal analysis.[7][8] The practical point for readers is simpler: Lilly has announced a planned BLA, but no application has yet been approved.

Why this does not validate gray-market retatrutide

The trials evaluate a specific investigational product made, stored and administered under a controlled development program. An online vial carrying the same ingredient name is not thereby shown to be the same product. Sequence, strength, counter-ion, formulation, impurity profile, sterility and stability remain separate questions.

That gap is especially important while demand precedes approval. “Research use only” is a statement about intended laboratory use, not clinical equivalence to Lilly’s investigational drug. Phase 3 success validates neither an online vendor nor a dosing protocol assembled from social media.

Questions people are asking